IDiyas

For the Inventor, By the Inventor

Rockport, MA, United States of America

Paul A Colussi

USPTO Granted Patents = 16


Average Co-Inventor Count = 3.1

ph-index = 3

Forward Citations = 37(Granted Patents)


Location History:

  • Rockport, MA (US) (2005)
  • Gloucester, MA (US) (2006 - 2023)

Company Filing History:

goldMedal13 out of 336 
 
New England Biolabs, Inc.
 patents
silverMedal3 out of 4 
 
Tetragenetics, Inc.
 patents

Years Active: 2005-2023

Loading Chart...
Loading Chart...
16 patents (USPTO):Explore Patents
1. 11597763 - Anti-Kv1.3 antibodies, and methods of production and use thereof (2023-03-07),
2. 9512181 - Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor (2016-12-06),
3. 8664374 - Polypeptide expression in ciliates (2014-03-04),
4. 8647855 - Genetically engineered yeast for the production of biofuels (2014-02-11),
5. 8623615 - Solubilization and purification of a target protein fused to a mutant maltose-binding protein (2014-01-07),
6. 8486660 - Methods and compositions for concentrating secreted recombinant protein (2013-07-16),
7. 8361750 - [object Object] (2013-01-29),
8. 8288337 - Compositions and methods relating to elutable carbohydrate-binding proteins (2012-10-16),
9. 8119390 - Methods and compositions for concentrating secreted recombinant proteins (2012-02-21),
10. 7883867 - Solubilization and purification of a target protein fused to a mutant maltose-binding protein (2011-02-08),
11. 7825218 - Solubilization and purification of a target protein fused to a mutant maltose-binding protein (2010-11-02),
12. 7732565 - Compositions and methods relating to elutable carbohydrate-binding proteins (2010-06-08),
13. 7517671 - Methods and compositions for concentrating secreted recombinant protein (2009-04-14),
14. 7390636 - [object Object] (2008-06-24),
15. 7060465 - Modified chitin binding domain and uses thereof (2006-06-13),

Title: The Inventor Extraordinaire: Paul A Colussi

Introduction:

Meet Paul A Colussi, a prolific inventor hailing from Rockport, MA, US, with an impressive portfolio of 16 patents to his name. His innovative spirit and dedication to scientific advancement have resulted in groundbreaking inventions that have the potential to revolutionize the medical field.

Latest Patents:

1. Anti-Kv1.3 antibodies, and methods of production and use thereof: Paul A Colussi's latest patent showcases his expertise in developing Anti-Kv1.3 monoclonal antibodies that have high affinity for Kv1.3 and can inhibit its function. These antibodies hold promise as therapeutics for autoimmune disorders, providing new avenues for treatment.

2. Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses therefor: Another recent invention by Paul A Colussi involves the production of immunogenic granular particles, particularly in ciliates. The fusion polypeptides developed have the potential for use in immunological applications, paving the way for innovative medical solutions.

Career Highlights:

Paul A Colussi has made significant contributions to the scientific community through his work with esteemed companies like New England Biolabs, Inc. and Tetragenetics, Inc. His expertise and innovative mindset have positioned him as a thought leader in the field of biotechnology, driving progress and advancements in medical research.

Collaborations:

Throughout his career, Paul A Colussi has collaborated with talented individuals such as Christopher H Taron and Paul Riggs. These collaborations have resulted in fruitful partnerships, leading to the development of novel inventions and advancements in the biotechnology industry.

Conclusion:

In conclusion, Paul A Colussi's dedication to innovation and his relentless pursuit of scientific excellence have solidified his position as a leading inventor in the field of biotechnology. His patents stand as a testament to his creativity and vision, with the potential to impact lives and drive progress in the medical field for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…